Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow reserve (TTDE-CFR), can be used to measure drug effects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator |
| |
| 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rosuvastatin | Drug | 40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in CFR peak velocity within rosuvastatin group after 1 month of treatment compared to baseline | Baseline and after 1 month of treatment | |
| Comparison of treatment effects on CFR peak velocities between groups after 1 month of treatment | Baseline and after 1 month of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in CFR peak velocity within the rosuvastatin group after 3 months compared to baseline and to 1 month | Bseline, after 1 month and after 3 months of treatment | |
| Changes in other CFR parameters after one month rosuvastatin or placebo treatment; comparisons within groups and between groups |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Björn Fagerberg, MD, Professor | Wallenberg LaboratorySahlgrenska University Hospital, S-413 45 Göteborg | Principal Investigator |
| Maria Leonsson-Zachrissson, MD | AstraZeneca R&D Mölndal | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Gothenburg | Sweden |
Not provided
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068718 | Rosuvastatin Calcium |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D005464 | Fluorobenzenes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Tablet, oral, once daily for 1 month (double blind) |
|
| Baseline and after 1 month of treatment |
| Changes in plasma lipids, lipoproteins and other cardiovascular biomarkers after 1 month of treatment with rosuvastatin or placebo; comparisons within groups and between groups | Baseline and after 1 month of treatment |
| D006845 |
| Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |